We analyzed combined data from two mature phase III randomized trials conducted by the Eastern Cooperative Oncology Group ( ECOG ; trial E1393 , which compared cisplatin plus paclitaxel at two dose levels , and trial E1395 , which compared cisplatin plus fluorouracil to cisplatin plus paclitaxel ) to evaluate the toxicity , objective response rates , and survival of patients 70 years or older versus their younger counterparts .
